## Krystallenia I Alexandraki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8329346/publications.pdf

Version: 2024-02-01

154 papers 4,593 citations

126708 33 h-index 63 g-index

161 all docs

161 docs citations

times ranked

161

5585 citing authors

#	Article	IF	CITATIONS
1	Aggressive Pituitary Tumors. Neuroendocrinology, 2015, 101, 87-104.	1.2	430
2	Inflammatory Process in Type 2 Diabetes: The Role of Cytokines. Annals of the New York Academy of Sciences, 2006, 1084, 89-117.	1.8	255
3	Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction, 2006, 21, 1426-1431.	0.4	225
4	The ectopic ACTH syndrome. Reviews in Endocrine and Metabolic Disorders, 2010, 11, 117-126.	2.6	181
5	Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology, 2005, 152, 749-756.	1.9	161
6	Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. European Journal of Endocrinology, 2013, 168, 639-648.	1.9	156
7	Inflammatory and endothelial markers in women with polycystic ovary syndrome. European Journal of Clinical Investigation, 2006, 36, 691-697.	1.7	141
8	Failure of Mathematical Indices to Accurately Assess Insulin Resistance in Lean, Overweight, or Obese Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1273-1276.	1.8	136
9	Cytokine Secretion in Long-standing Diabetes Mellitus Type 1 and 2: Associations with Low-grade Systemic Inflammation. Journal of Clinical Immunology, 2008, 28, 314-321.	2.0	113
10	Endocrine manifestations in Langerhans cell histiocytosis. Trends in Endocrinology and Metabolism, 2007, 18, 252-257.	3.1	111
11	Patients With Apparently Nonfunctioning Adrenal Incidentalomas May Be at Increased Cardiovascular Risk Due to Excessive Cortisol Secretion. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2754-2762.	1.8	108
12	Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing's disease. European Journal of Endocrinology, 2011, 164, 667-674.	1.9	93
13	MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause. European Journal of Endocrinology, 2015, 172, R79-R91.	1.9	86
14	The prevalence and characteristic features of cyclicity and variability in Cushing's disease. European Journal of Endocrinology, 2009, 160, 1011-1018.	1.9	82
15	Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. European Journal of Endocrinology, 2013, 168, 185-193.	1.9	80
16	Metastatic type 1 gastric carcinoid: A real threat or just a myth?. World Journal of Gastroenterology, 2013, 19, 8687.	1.4	76
17	The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. European Journal of Endocrinology, 2004, 150, 793-798.	1.9	73
18	Effectiveness of artificial pancreas in the non-adult population: A systematic review and network meta-analysis. Metabolism: Clinical and Experimental, 2019, 90, 20-30.	1.5	71

#	Article	IF	Citations
19	Long-acting somatostatin analogues are an effective treatment for type $1\mathrm{gastric}$ carcinoid tumours. European Journal of Endocrinology, 2008, 159, 475-482.	1.9	69
20	Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2007, 56, 129-134.	1.5	67
21	Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine, 2012, 41, 40-52.	1.1	58
22	Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocrine-Related Cancer, 2016, 23, R27-R41.	1.6	58
23	Current Size Criteria for the Management of Neuroendocrine Tumors of the Appendix: Are They Valid? Clinical Experience and Review of the Literature. Neuroendocrinology, 2013, 98, 31-37.	1.2	57
24	Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Annals of Translational Medicine, 2018, 6, 252-252.	0.7	56
25	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	5.5	55
26	Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 109, 333-345.	1.2	52
27	Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clinical Biochemistry, 2007, 40, 336-342.	0.8	50
28	Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology, 2006, 66, 061031010617005-???.	1.2	47
29	Is urinary free cortisol of value in the diagnosis of Cushing $\hat{E}\frac{1}{4}$ s syndrome?. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 259-263.	1.2	47
30	Association between chronic pelvic pain symptoms and the presence of endometriosis. Archives of Gynecology and Obstetrics, 2016, 293, 439-445.	0.8	45
31	Antithyroid Drug-Induced Aplastic Anemia. Thyroid, 2008, 18, 1043-1048.	2.4	38
32	Gastric Carcinoids. Endocrinology and Metabolism Clinics of North America, 2018, 47, 645-660.	1.2	38
33	Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy. Journal of Endocrinology, 2020, 246, R13-R31.	1.2	37
34	Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clinical Endocrinology, 2015, 83, 420-428.	1.2	36
35	Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones, 2006, 5, 126-136.	0.9	34
36	Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2006, 55, 494-500.	1.5	33

#	Article	IF	CITATIONS
37	The knowledge of osteoporosis risk factors in a Greek female population. Maturitas, 2008, 59, 38-45.	1.0	33
38	Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome. Drugs, 2016, 76, 447-458.	4.9	33
39	Management of neuroendocrine tumors of unknown primary. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 423-431.	2.6	32
40	Management of Hypopituitarism. Journal of Clinical Medicine, 2019, 8, 2153.	1.0	32
41	Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones, 2012, 11, 297-307.	0.9	31
42	Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged followâ€up. Clinical Endocrinology, 2017, 86, 488-498.	1.2	31
43	Neoplastic metastases to the endocrine glands. Endocrine-Related Cancer, 2020, 27, R1-R20.	1.6	31
44	Assessment of serumâ€free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology, 2010, 72, 305-311.	1.2	30
45	Presence of metabolic risk factors in non-obese PCOS sisters: Evidence of heritability of insulin resistance. Journal of Endocrinological Investigation, 2004, 27, 931-936.	1.8	29
46	Clinical value of right hemicolectomy for appendiceal carcinoids using pathologic criteria. Journal of Endocrinological Investigation, 2011, 34, 255-259.	1.8	29
47	Novel Insights in the Diagnosis of Cushing's Syndrome. Neuroendocrinology, 2010, 92, 35-43.	1.2	28
48	Acetyl Cholinesterase Inhibitors and Cell-Derived Peripheral Inflammatory Cytokines in Early Stages of Alzheimer's Disease. Journal of Clinical Psychopharmacology, 2018, 38, 138-143.	0.7	27
49	Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Â-Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine. Clinical Infectious Diseases, 2014, 59, 862-865.	2.9	26
50	The Medical Therapy of Craniopharyngiomas: The Way Ahead. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5751-5764.	1.8	26
51	Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2013, 33, 165-170.	0.4	25
52	Current concepts in the diagnosis and management of type $1$ gastric neuroendocrine neoplasms. Clinical Endocrinology, 2014, 81, 157-168.	1.2	25
53	Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. BioMed Research International, 2017, 2017, 1-12.	0.9	25
54	Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors. Pancreas, 2019, 48, 934-942.	0.5	24

#	Article	IF	CITATIONS
55	The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. Journal of Endocrinological Investigation, 2010, 33, 794-799.	1.8	22
56	Hypophysitis in IgG4-Related Disease Associated with p-ANCA Vasculitis. American Journal of Medicine, 2016, 129, e25-e27.	0.6	22
57	Corticomedullary Mixed Adrenal Tumor: Case Report and Literature Review. Endocrine Journal, 2009, 56, 817-824.	0.7	21
58	<p>Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies</p> . Cancer Management and Research, 2020, Volume 12, 9551-9561.	0.9	21
59	Hypophysitis (Including IgG4 and Immunotherapy). Neuroendocrinology, 2020, 110, 822-835.	1.2	21
60	Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?. Clinical Endocrinology, 2014, 80, 685-690.	1.2	20
61	Pituitary-targeted medical therapy of Cushing's disease. Expert Opinion on Investigational Drugs, 2008, 17, 669-677.	1.9	19
62	Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms). Medicine (United) Tj ETQq0	0 O rgBT /0	Overlock 10 Ti
63	Adrenal incidentalomas: †the rule of four'. Clinical Medicine, 2008, 8, 201-204.	0.8	18
64	Diagnostic accuracy and clinical significance of the fine needle aspiration Ki-67 labelling index in pancreatic endocrine tumours. Endocrine-Related Cancer, 2011, 18, L1-L3.	1.6	18
65	Isolated adrenocorticotropin deficiency and flexion contractures syndrome. Hormones, 2008, 7, 320-324.	0.9	17
66	Specific electrocardiographic features associated with Cushing's disease. Clinical Endocrinology, 2011, 74, 558-564.	1.2	17
67	The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice. Endocrine, 2019, 64, 690-701.	1.1	17
68	The risk of lymph node metastases and their impact on survival in patients with appendiceal neuroendocrine neoplasms: a systematic review and meta-analysis of adult and paediatric patients. Endocrine, 2020, 67, 20-34.	1.1	16
69	Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin. Minerva Endocrinologica, 2020, 44, 378-386.	1.7	15
70	Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. QJM - Monthly Journal of the Association of Physicians, 2007, 101, 31-40.	0.2	14
71	Recurrence and metastatic potential in Type $1$ gastric neuroendocrine neoplasms. Clinical Endocrinology, 2019, 91, 534-543.	1.2	14
72	Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 1777.	1.0	14

#	Article	IF	CITATIONS
73	IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms. Oncotarget, 2017, 8, 79003-79011.	0.8	14
74	Medical Therapy of Cushing's Disease: Where Are We Now?. Frontiers of Hormone Research, 2010, 38, 165-173.	1.0	13
<b>7</b> 5	Malignant Pheochromocytomas/Paragangliomas and Ectopic Hormonal Secretion: A Case Series and Review of the Literature. Cancers, 2019, 11, 724.	1.7	13
76	Changing biological behaviour of NETs during the evolution of the disease: progress on progression. Endocrine-Related Cancer, 2021, 28, R121-R140.	1.6	12
77	Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma. European Journal of Clinical Investigation, 2012, 42, 1165-1172.	1.7	11
78	Predictive Value of Gastrin Levels for the Diagnosis of Gastric Enterochromaffin-Like Cell Hyperplasia in Patients with Hashimoto's Thyroiditis. Neuroendocrinology, 2014, 99, 118-122.	1.2	11
79	Increased autophagy/mitophagy levels in primary tumours of patients with pancreatic neuroendocrine neoplasms. Endocrine, 2020, 68, 438-447.	1.1	11
80	Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocrine Connections, 2019, 8, 641-653.	0.8	11
81	Increased incidence of papillary thyroid cancer detection among thyroidectomies in Greece between 1991 and 2006. Anticancer Research, 2009, 29, 5163-9.	0.5	11
82	The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 242-246.	0.5	10
83	Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance. Neuroendocrinology, 2019, 108, 308-316.	1.2	10
84	Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Hormone and Metabolic Research, 2020, 52, 25-31.	0.7	9
85	Magnetic Resonance Imaging or Endoscopic Ultrasonography for Detection and Surveillance of Pancreatic Neuroendocrine Neoplasms in Patients with Multiple Endocrine Neoplasia Type 1?. Hormone and Metabolic Research, 2019, 51, 580-585.	0.7	8
86	Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends in Endocrinology and Metabolism, 2020, 31, 239-255.	3.1	8
87	The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN. Endocrine, 2020, 70, 178-186.	1.1	8
88	Expression of clock-related genes in benign and malignant adrenal tumors. Endocrine, 2020, 68, 650-659.	1.1	8
89	Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease. Endocrine, 2021, 72, 279-286.	1.1	8
90	Currently available treatment options for neuroendocrine liver metastases. Annals of Gastroenterology, 2021, 34, 130-141.	0.4	8

#	Article	IF	CITATIONS
91	Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. Hormone and Metabolic Research, 2020, 52, 614-620.	0.7	7
92	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. European Endocrinology, 2021, 17, 37.	0.8	7
93	Transcriptomics, Epigenetics, and Metabolomics of Primary Aldosteronism. Cancers, 2021, 13, 5582.	1.7	7
94	Endocrinopathies and Other Disorders Inducing a Polycystic Ovary Syndrome Phenotype. Frontiers of Hormone Research, 2012, 40, 142-157.	1.0	6
95	Medical Therapy for Craniopharyngiomas. European Endocrinology, 2021, 17, 121.	0.8	6
96	Primary Hyperparathyroidism in Patients with Gastric Carcinoid Tumors Type 1: An Unusual Coexistence. Neuroendocrinology, 2010, 92, 252-258.	1.2	5
97	Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues. Journal of Personalized Medicine, 2019, 9, 48.	1.1	5
98	Medical Therapy for Cushing's Disease – Past and Future Modes of Treatment. European Endocrinology, 2008, 4, 74.	0.8	5
99	Light sensitivity and pain sensation during cataract surgery. A comparative study of two modes of anaesthesia. International Ophthalmology, 2010, 30, 703-707.	0.6	4
100	Differential Expression of Apoptotic and Low-Grade Inflammatory Markers in Alzheimer Disease Compared to Diabetes Mellitus Type 1 and 2. journal of applied laboratory medicine, The, 2019, 3, 1003-1013.	0.6	4
101	Long-term sequelae of the less than total thyroidectomy procedures for benign thyroid nodular disease. Endocrine, 2019, 63, 247-251.	1.1	4
102	Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine, 2021, 73, 232-239.	1.1	4
103	Neuroendocrine neoplasms: Evolving and future treatments. Current Opinion in Endocrine and Metabolic Research, 2021, 19, 15-21.	0.6	4
104	Hobnail Papillary Thyroid Carcinoma, A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 2785.	1.7	4
105	Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application. Hormones and Cancer, 2018, 9, 144-155.	4.9	3
106	A cohort-based comprehensive characterization of different patterns of very short-term, within-visit, blood pressure variability. Blood Pressure Monitoring, 2020, 25, 131-135.	0.4	3
107	Very-short-term blood pressure variability: complexities and challenges. Blood Pressure Monitoring, 2020, 25, 300-300.	0.4	3
108	Adrenal Failure and Orchitis Secondary to Tuberculosis Mimicking Metastatic Malignancy. American Journal of Medicine, 2020, 133, e518-e520.	0.6	3

#	Article	IF	Citations
109	Cushing's Syndrome. , 2014, , 99-111.		3
110	"The past is a different country, they do things differently there― using the SEER data-base to assess prognosis in neuroendocrine tumours. Endocrine, 2022, 75, 725-727.	1.1	3
111	The acute effect of Orlistat on dietary glycotoxins in diabetics and healthy women. Minerva Endocrinologica, 2009, 34, 97-104.	1.7	3
112	Secondary Polycythemia Attributed To An Incidentally Discovered Luteinizing Hormone–Secreting Pituitary Adenoma: A Case Report. AACE Clinical Case Reports, 2017, 3, e54-e58.	0.4	2
113	Association of skin autofluorescence with arterial properties: A closer look at AGE Reader and EndoPAT 2000 commercial devices. Experimental Gerontology, 2017, 98, 207-208.	1.2	2
114	The role of palbociclib in thyroid carcinoma with BRAF mutation. Gland Surgery, 2018, 7, S82-S85.	0.5	2
115	Metabolic syndrome and atopic dermatitis: reconsidering the definition criteria. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e130-e131.	1.3	2
116	Accuracy of adrenal imaging modalities in predicting histological tumor dimension following adrenalectomy. Archives of the Balkan Medical Union, 2020, 55, 375-381.	0.1	2
117	Incidence of Pituitary Incidentalomas in Patients with Adrenal Adenomas. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 15-19.	0.6	1
118	The early benefits of Laparoscopic Sacrocolpopexy. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, 799-804.	0.6	1
119	Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration―Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms― Neuroendocrinology, 2020, 110, 158-160.	1.2	1
120	Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 542.	0.6	1
121	Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests. Hormones, 2021, 20, 359-368.	0.9	1
122	Augmentation index in the assessment of pulse wave reflection assessment in lean and obese women with polycystic ovary syndrome (PCOS). Endocrine Abstracts, 0, , .	0.0	1
123	Emergency Treatment of Florid Cushing's Syndrome. , 2014, , 159-164.		1
124	Immunohistochemical expression of ephrines A2 and A4 receptors in neuroendocrine neoplasms: preliminary results. Endocrine Abstracts, 0, , .	0.0	1
125	Adrenal insufficiency and pregnancy. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 277-283.	1.2	1
126	Current strategies for the treatment of severe Cushing's syndrome. Expert Review of Endocrinology and Metabolism, 2016, 11, 65-79.	1.2	0

#	Article	IF	CITATIONS
127	A prolapsing pituitary adenoma. Endocrine, 2020, 67, 501-502.	1.1	O
128	The diagnosis of Cushing's disease. , 2021, , 219-229.		O
129	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. European Endocrinology, 2021, 1, 37.	0.8	0
130	ACTH-Dependent Cushing Syndrome: Clinical and Diagnostic Aspects, and Treatment Approaches for Ectopic Cushing $\hat{\mathbf{e}}^{\mathrm{IM}}$ Syndrome., 2010, , 163-176.		0
131	Expression of somatostatin and dopamine receptors in neuroendocrine tumors: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Endocrine Abstracts, 0, , .	0.0	0
132	Metastatic bone disease in patients with neuroendocrine tumors. Endocrine Abstracts, 0, , .	0.0	0
133	Sunitinib induced hypocalcaemia during treatment of pancreatic neuroendocrine tumours. Endocrine Abstracts, 0, , .	0.0	O
134	Patients with multiple endocrine neoplasia type 1 (MEN1) have late progression and long survival despite the presence of disseminated disease: the experience of a referral centre in Greece. Endocrine Abstracts, $0, , .$	0.0	0
135	The higher gastrin levels were associated with better glycaemic control. Endocrine Abstracts, 0, , .	0.0	0
136	Optic neuropathy following radiotherapy for Cushing's disease followed by the diagnosis of pituitary carcinoma. Endocrine Abstracts, 0, , .	0.0	0
137	A case series of etomidate use in ACTH ectopic syndrome in endocrine neoplasms. Endocrine Abstracts, 0, , .	0.0	0
138	Higher glucose levels and prevalence of prediabetes in patients with autoimmune thyroiditis. Endocrine Abstracts, 0, , .	0.0	0
139	Patients with neuroendocrine neoplasms: the experience of a referral centre in Greece. Endocrine Abstracts, 0, , .	0.0	0
140	The prevalence of pancreatic neuroendocrine neoplasms with dedifferentiation during their natural history. Endocrine Abstracts, 0, , .	0.0	0
141	Mechano growth factor (MGF) expression increased in secondary compared to primary foci in well neuroendocrine neoplasms. Endocrine Abstracts, 0, , .	0.0	0
142	Deterioration of indices of insulin resistance in patients with non-functioning and cortisol secreting adrenal incidentalomas during a long term follow-up. Endocrine Abstracts, 0, , .	0.0	0
143	The impact of thyroid autoimmunity on insulin secretion in pre-diabetic patients with normal thyroid function. Endocrine Abstracts, 0, , .	0.0	0
144	Long term effects of the less than total thyroidectomy: The experience of a tertiary care center. Endocrine Abstracts, 0, , .	0.0	0

#	Article	IF	Citations
145	Large intestinal metaplasia is a precancerous lesion present in patients with gastric neuroendocrine neoplasms type 1. Endocrine Abstracts, $0$ , , .	0.0	0
146	Patients with metastatic bone disease and neuroendocrine neoplasms: the experience of a multi-center study. Endocrine Abstracts, 0, , .	0.0	0
147	Clinical features of a gastric neuroendocrine neoplasms type $1$ series. Endocrine Abstracts, $0,  ,  .$	0.0	0
148	Differentiating Cushing from Pseudo-Cushing. Endocrine Abstracts, 0, , .	0.0	0
149	Non-alcoholic fatty liver disease and polycystic ovarian syndrome in lean and obese women of reproductive age. Endocrine Abstracts, 0, , .	0.0	0
150	Accuracy of adrenal imaging studies in predicting histological tumor dimension following adrenalectomy. Endocrine Abstracts, 0, , .	0.0	0
151	The role of somatostatin analogs in the control of carcinoid syndrome: systematic review and meta-analysis. Endocrine Abstracts, 0, , .	0.0	O
152	Thyroid Autoimmunity Has No Negative Impact On Insulin Dynamics In Prediabetic Patients With Normal Thyroid Function. Archives of the Balkan Medical Union, 2020, 55, 215-223.	0.1	0
153	Surgical outcomes of adrenalectomy for primary hyperaldosteronism after using novel diagnostic tests. Endocrine Abstracts, 0, , .	0.0	0
154	The greek hospital and pharmacies of Smyrna (1723–1922). AMHA - Acta Medico-Historica Adriatica, 2021, 19, 271-280.	0.0	0